There is a need to reassess contemporary oral anticoagulation (OAC) trends and barriers
against guideline directed therapy in the United States. Most previous studies were …

Abstract Aims Using Scandinavian population-based registries, we assessed risk of
stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral …

Background: New oral anticoagulant agents (NOACs) are valid alternatives for vitamin K
antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF) for stroke prevention …

Purpose Patients with nonvalvular atrial fibrillation commonly have comorbidities requiring
concurrent use of oral anticoagulants and antiplatelets. There are no real-world data on the …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

Background In patients with non‐valvular atrial fibrillation (AF), direct‐acting oral
anticoagulants (DOACs) are at least non‐inferior to warfarin for the prevention of stroke and …

Direct oral anticoagulants (DOACs) are used by most anticoagulated patients with atrial
fibrillation (AF) in contemporary practice. Whether pivotal randomized controlled trials …

Purpose The use of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF)
and bioprosthetic heart valve is still controversial. The aim of this study was to compare the …

No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …